We have been exploring novel ways to accelerate rare disease trial enrollment to achieve our objective of reducing the time between FPI and LPI by 33%. With this reduction, we will enable patients to access therapy more quickly, accelerate development milestones, and reduce the cost of conducting trials for our sponsors. Developing a patient portal is one method we have been exploring to achieve this objective.
Check out this white paper for an overview of the patient portal we developed and piloted and its objectives, methods, outcomes, and subsequent modifications. Download our white paper today to learn more about our portal and how it could help your study enroll faster.
Authors:
Martin Cummins
Executive Director, Project Management
Michael Murphy, MD, PhD
Chief Medical and Scientific Officer
